What is Condor?
Condor operates as a high-growth technology firm dedicated to the biopharmaceutical and life sciences industries. Its flagship platform serves as a critical financial intelligence engine, automating the intricate processes associated with clinical research budgeting, forecasting, and vendor management. By providing real-time visibility into R&D workflows, the company enables organizations to optimize their capital allocation and improve operational efficiency. In a market characterized by high-stakes research and stringent regulatory requirements, Condor's software provides the necessary precision to manage complex financial data, ensuring that life sciences firms can maintain fiscal discipline while pursuing scientific innovation.
How much funding has Condor raised?
Condor has raised a total of $24M across 1 funding round:
Series A
$24M
Series A (2026): $24M with participation from Bramalea Partners, Felicis Ventures, Insight Partners, 645 Ventures, and Snr
Key Investors in Condor
Bramalea Partners
Bramalea Partners specializes in partnering with exceptional expansion-stage technology companies, focusing on growth-oriented investments to assist management teams in achieving sustainable and capital-efficient growth.
Felicis Ventures
Felicis is a Menlo Park-based venture capital firm that raises multistage funds to invest in early and growth-stage technology companies across sectors such as SaaS, AI, and fintech.
Insight Partners
Insight Partners is a global venture capital and private equity firm that invests in high-growth software and technology companies, providing capital and operational support to help businesses scale from early stage to IPO.
What's next for Condor?
With this major strategic investment, Condor is well-positioned to scale its enterprise-level operations and expand its footprint within the global life sciences market. The company is expected to prioritize the enhancement of its automated financial intelligence suite, potentially integrating advanced predictive analytics to further refine R&D forecasting. As the firm transitions from its current growth phase, the focus will likely shift toward deepening its integration with existing clinical trial management systems and expanding its client base among mid-to-large-cap biopharmaceutical organizations. This capital deployment will be instrumental in maintaining the company's competitive edge as it continues to digitize the financial backbone of clinical research.
See full Condor company page
